RCAN1 and neoplasm: Having demonstrated specific recognition of the RCAN1-422-32 epitope and tumor cell lysis of RCAN1-4pos human GBM cells by TCRC3-1- and TCRC6-2-engineered human T cells (TCR-TC3-1 and TCR-TC6-2, respectively), we next aimed to assess their therapeutic potential in vivo.